GlaxoSmithKline added to its cancer portfolio June 14 by signing an agreement with iTeos Therapeutics to co-develop and co-commercialize its experimental monoclonal antibody treatment for cancer.
The treatment, called EOS-448, is in a phase 1 study involving patients with advanced solid tumours. GlaxoSmithKline and iTeos plan to begin testing the treatment's administration with dostarlimab, another cancer antibody, in 2022.
GlaxoSmithKline will pay iTeos $625 million upfront, as well as up to $1.45 billion in potential milestones payments.